

COVID Vaccination Process for Patients receiving Cancer Treatments, Immunosuppressed, Renal & Pre- Operative Patients
SOP
1.3
20/02/2021
31/12/2021
Dr J Chalmers
Fiona Mann
Fiona Mann/J Chalmers
F Mann/C Faldon
N/R





COVID Vaccination process for patients receiving cancer treatments, immuno renal & pre op patients.

Objective/scope	The aim of this document is to provide guidance for staff ensuring		
	patients receiving cancer treatments; immunosuppressed, renal &		
	pre-op patients receive COVID vaccinations.		
Tasks – Clinical staff	Charge Nurse or Consultant identify & compile list of any of		
	the above patients requiring vaccination.		
	Email list to : Vacc.HubSupervisors@borders.scot.nhs.uk		
Tasks – Vaccination	Notify Vac Hub of clinic availability by 3pm the day before		
Programme Operational			
Manager			
Tasks – Hub Supervisors	Vac Hub to contact patient with appointment in either OPD		
	at weekly Tues clinic (staffed by 1 nurse from the Hub) or at		
	the next available community clinic.		
	Hub will also allocate appt for 2nd immunisation.		
	Notify nurse booked for Tuesday, of clinic list.		
Pre op patients	 Pre-op patients should have 2nd immunisation, 10 weeks after 1st dose. 		
Immunosuppressed	 Patients are all in shielding category – should have had 		
patients	vaccination at GP practice or at community clinic.		
	Any patient in this category who has not had their 1st		
	vaccination – clinician to contact Hub to have patient added to clinic list		
	• 2nd immunisation should be given 21 days apart with the Pfizer vaccine and 28 days apart with the AZ vaccine. See extract from Green Book below.		
Dialysis patients	• GP Practices have vaccinated all their dialysis patients –EMIS PCS recall system.		
Patients receiving cancer	Patients receiving systemic anticancer therapy (SACT) should		
treatments	be considered as having "planned immunosuppressive		
	therapy". Guidance from the UK Chemotherapy Board		
	says:"If there is sufficient time between the decision to start		
	treatment and the start date, vaccination should take place		
	during this window when the patient has intact immune		
	function Where timing (e.g. in planned adjuvant		
	chemotherapy) would allow both doses (i.e. the second dose		
	given at week 3 or 4 depending on the product) to be given		
	 before commencing chemotherapy" This can be organised by the clinician contacting the Hub to 		
	 This can be organised by the chinician contacting the Hub to have patient added to clinic list or by completing the form 		
	from the CMO letter of 9 March 2021 and forwarding this to		
	the Hub – attached.		

Green Book Chapter 14a	Individuals with immunosuppression may not make a full immune
COVD-19 – SARS-CoV-2	response to vaccination. As there is no evidence on response in
	immunosuppressed individuals there is also no evidence upon which
	to base advice on the optimal timing of delivery. Specialists may
	advise their patients based on their knowledge and understanding of
	their immune status and likely immune response to vaccination, but
	should also consider the risk from COVID-19 and the patient's
	likelihood of exposure. The small number of patients who are about
	to receive planned immunosuppressive therapy should be considered
	for vaccination prior to commencing therapy (ideally at least two
	weeks before), when their immune system is better able to make a
	response. Where possible, it would also be preferable for the 2-dose
	schedule to be completed prior to commencing immunosuppression.
	This would entail offering the second dose at the recommended
	minimum for that vaccine (three or four weeks from the first dose) to
	provide maximum benefit that may not be received if the second
	dose was given during the period of immunosuppression.
CMO referral	See Annex B

Annex B COVID-19 Vaccination Referral Form

REFERRAL FOR COVID-19 VACCINATION			
For Health Board Contact Detail	s, please see the accompanying list		
Date of Referral:			
Referring Clinician Name:	Email:		
Responsible Consultant/GP:	Specialty:		
Referring Hospital/ GP Practice:			
Patient Name:			
CHI:			
Telephone Number:			
 Commencing Immunosuppressive Therap High risk Haematology patients not alread groups 4 or 6 Other 	-		
If new treatment/surgery, anticipated start date: Need for second dose before 12 weeks? Preferred timeframe (eg. 3/4 weeks)?	YES 🗆 NO 🗆		
If contacting to expedite second dose only:	I		
Date of first dose:			
Preferred timeframe for second dose	weeks		
Any other comment:			
Please note that you should send your referral for vaccination to the Health Board of your patient's residence rather than where the person is attending for clinical care			

www.gov.scot

INVESTORS Accredited

Validation date	Date of implementation
Review period	ТВС
Authors	Fiona Mann, Senior Charge Nurse